Ema committee for medicinal products for human use adopts positive opinion recommending marketing authorization of moderna's rsv vaccine, mresvia(r)

Cambridge, ma / accesswire / june 28, 2024 / moderna, inc. (nasdaq:mrna) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending the granting of marketing authorization in the european union for mresvia (mrna-1345), an mrna respiratory syncytial virus (rsv) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by rsv infection. following the chmp's positive opinion, the european commission will adopt a decision on the authorization of mresvia.
MRNA Ratings Summary
MRNA Quant Ranking